Zealand Pharma · DK0060257814 · ZEAL | XCSE | Prime AI Terminal

CUSIP

K9898X127

SEDOL

B0SDJB4

CIK

0001674988

zealandpharma.com

LEI: 549300ITBB1ULBL4CZ12

BASIC = Free ADVANCED = User Account BUSINESS = Subscription PRIME = Subscription

ENTERPRISE = upon request

PROFILER

BASIC

ADVANCED

BUSINESS

PRIME

AI Insights

Zealand Pharma

Click to initiate

ENTERPRISE

Securities Trading Warrants

GlobeNewswire is an important news source that provides investors with company-related information. In particular, it deals with events that may be relevant to the listing of companies or tradable financial instruments. You can access the complete overview of all reports via this link.

Thu, 20.02.2025

Company announcement – No. 2 / 2025

Research & Analysis

Thu, 20.02.2025

Company announcement – No. 2 / 2025

Research & Analysis

Thu, 13.02.2025

Press Release – No. 3 / 2025

Research & Analysis

Mon, 13.01.2025

Company announcement – No. 1 / 2025

Research & Analysis

Tue, 07.01.2025

Press Release – No. 2 / 2025

Research & Analysis

Mon, 06.01.2025

Press Release – No. 1 / 2025

Research & Analysis

Wed, 25.12.2024

Company announcement – No. 53 / 2024

Research & Analysis

Wed, 25.12.2024

Company announcement – No. 52 / 2024

Research & Analysis

Thu, 19.12.2024

Company announcement – No. 51 / 2024

Research & Analysis

Tue, 10.12.2024

Press Release – No. 12 / 2024

Research & Analysis

We are different

OPEN FINANCIAL

DATA & KNOWLEDGE HUB

We make the difference

Information on product placements

SMART * AD

P R O D U C T S U G G E S T I O N S

Subject *

i.e Feature x is not working

Issue happened on *

This page

Other page

Page URL

Paste the page URL here

Bug Detail *

Please give us more detailed explanation of the issue

Steps to reproduce *

Specify the steps you've done before the issue happen

Actual Result *

What's the result of the issue?

Expected Result *

What do you expect to see?

Attachment

(Optional) You can send us a screenshot, word document, or a PDF explaining the issue

You have pressed the "". We would like to inform you that you are now leaving the information service of the portal site ayondo.com. You will be redirected to . After confirming the "Continue" button, you confirm that you have been informed of this. You also confirm that you are carrying out this process of your own free will and that it is not the result of any promotional activity or other influence. Continue to .

I would like to remain anonymous.

Subject *

e.g. New calculation method for Risk-of-Ruin-Calculator

View/Tool *

This view/tool

Another page/tool

Description of the proposed change/feedback *

The more comprehensible the description, the faster a feasibility check can be carried out.

General feedback on the view/tool/component/content *

Use this feedback text field for general or supplementary information

Would you use the tool and recommend it if necessary? *

Your opinion is valuable. Feel free to share it with us.

Zealand Pharma A/S

Newsletter

Zealand Pharma A/S

Correction: Zealand Pharma Announces Financial Results for the Full Year 2024

Zealand Pharma Announces Financial Results for the Full Year 2024

Zealand Pharma conference call on February 20 at 2pm CET (8am ET) to present full year 2024 financial results

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Steven R. Smith, MD, joins Zealand Pharma as Senior Global Medical Advisor in Obesity

Zealand Pharma to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13th

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Zealand Pharma major shareholder announcement: The Capital Group Companies, Inc.

U.S. Food and Drug Administration issues Complete Response Letter for the glepaglutide New Drug Application for the treatment of short bowel syndrome

Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity

Newsletter